PROTAGONIST THERAPEUTICS, INC. Financials Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.41 USD | -0.43% |
|
-1.07% | +32.62% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 191.8 | 867.3 | 1,632 | 536.8 | 1,323 | 1,784 | - | - |
| Enterprise Value (EV) 1 | 68.58 | 561.4 | 1,305 | 411 | 1,136 | 1,342 | 1,106 | 1,784 |
| P/E ratio | -2.37 x | -10.5 x | -12.6 x | -4.2 x | -16.5 x | 26.4 x | -30.9 x | -30.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 830 x | 30.3 x | 59.7 x | 20.2 x | 22 x | 6.61 x | 14.9 x | 12.2 x |
| EV / Revenue | 297 x | 19.6 x | 47.7 x | 15.5 x | 18.9 x | 4.97 x | 9.24 x | 12.2 x |
| EV / EBITDA | - | -8.81 x | -10.4 x | - | -12.3 x | 16.4 x | 16 x | - |
| EV / FCF | -1.62 x | -7.7 x | -12 x | -3.77 x | -16 x | 10.2 x | -20.1 x | -16.5 x |
| FCF Yield | -61.8% | -13% | -8.35% | -26.5% | -6.24% | 9.8% | -4.97% | -6.06% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 27,206 | 43,019 | 47,728 | 49,198 | 57,678 | 58,652 | - | - |
| Reference price 2 | 7.050 | 20.16 | 34.20 | 10.91 | 22.93 | 30.41 | 30.41 | 30.41 |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.231 | 28.63 | 27.36 | 26.58 | 60 | 270 | 119.8 | 145.6 |
| EBITDA 1 | - | -63.73 | -125 | - | -92.68 | 82 | 69 | - |
| EBIT 1 | -80.52 | -64.52 | -125.8 | -131.4 | -93.65 | 80.11 | -24.47 | -59.27 |
| Operating Margin | -34,857.58% | -225.36% | -460.01% | -494.24% | -156.09% | 29.67% | -20.43% | -40.71% |
| Earnings before Tax (EBT) 1 | -77.88 | -64.84 | -125.6 | -127.4 | -78.96 | 95.39 | 12.01 | -47.31 |
| Net income 1 | -77.19 | -66.15 | -125.6 | -127.4 | -78.96 | 77.26 | 2.943 | -50.55 |
| Net margin | -33,414.29% | -231.07% | -458.94% | -479.26% | -131.59% | 28.62% | 2.46% | -34.72% |
| EPS 2 | -2.980 | -1.920 | -2.710 | -2.600 | -1.390 | 1.151 | -0.9842 | -0.9850 |
| Free Cash Flow 1 | -42.4 | -72.96 | -109 | -108.9 | -70.84 | 131.5 | -55 | -108 |
| FCF margin | -18,355.41% | -254.84% | -398.31% | -409.81% | -118.08% | 48.71% | -45.92% | -74.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 160.37% | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | 170.2% | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.617 | 25.72 | 0.859 | - | - | - | - | - | 60 | 255 | 6.667 | 0.8333 | 7.5 | - | 100 |
| EBITDA 1 | -36.78 | -20.86 | -41.18 | -32.03 | -36.26 | -35.77 | -42.12 | -38.08 | 23.3 | 206.5 | -44 | -45 | -36 | - | - |
| EBIT 1 | -37.02 | -21.11 | -41.44 | -32.3 | -36.52 | -36.02 | -42.35 | -38.33 | 23.05 | 206.3 | -39.76 | -46.15 | -40.27 | - | - |
| Operating Margin | -429.57% | -82.07% | -4,824.56% | - | - | - | - | - | 38.42% | 80.92% | -596.47% | -5,537.84% | -537% | - | - |
| Earnings before Tax (EBT) 1 | -36.91 | -20.93 | -41.04 | -31.23 | -34.19 | -33.72 | -38.46 | -34.1 | 27.34 | 210.7 | -42.86 | -43.3 | -29.18 | - | - |
| Net income 1 | -36.91 | -20.93 | -41.04 | -31.23 | -34.19 | -33.72 | -38.46 | -34.1 | 27.34 | 207.3 | -44.8 | -44.96 | -36.96 | - | - |
| Net margin | -428.3% | -81.37% | -4,777.3% | - | - | - | - | - | 45.56% | 81.32% | -671.95% | -5,395.51% | -492.8% | - | - |
| EPS 2 | -0.7700 | -0.4300 | -0.8400 | -0.6400 | -0.6900 | -0.6700 | -0.6800 | -0.5800 | 0.4400 | 3.260 | -0.7324 | -0.7350 | -0.6045 | -0.7650 | 0.6200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/4/22 | 8/4/22 | 11/8/22 | 3/15/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/27/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 123 | 306 | 327 | 126 | 187 | 442 | 677 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -42.4 | -73 | -109 | -109 | -70.8 | 132 | -55 | -108 |
| ROE (net income / shareholders' equity) | - | -36.8% | -43.3% | -49.4% | -28.6% | 24% | 11.5% | - |
| ROA (Net income/ Total Assets) | - | -27.6% | -37.4% | -42.8% | -26.1% | 21.7% | 10.6% | - |
| Assets 1 | - | 239.7 | 336.1 | 297.8 | 302.9 | 356 | 27.81 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.97 | 0.47 | 1.1 | 0.8 | 0.61 | - | - | - |
| Capex / Sales | 418.61% | 1.65% | 4.02% | 2.99% | 1.02% | - | - | - |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
30.41
USD
Average target price
43.5
USD
Spread / Average Target
+43.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.62% | 1.78B | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- PTGX Stock
- Financials Protagonist Therapeutics, Inc.
